BioLife today announced the launch of its new corporate brand identity, redesigned logo, and website. The new brand identity was created to better reflect BioLife’s expanded portfolio of bioproduction tools and services. Todd Berard, Chief Marketing Officer, remarked, “We pursued a refreshed design that appropriately positions BioLife as the premier supplier of cell and gene…
Read MoreBristol Myers Squibb’s Breyanzi Receives FDA Approval. Breyanzi is Cryopreserved in CryoStor® CS10. Earlier this year, the U.S. Food and Drug Administration published a press release announcing the approval of CD19-targeting CAR T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel). Breyanzi is approved to treat adult patients with relapsed or refractory large B-cell lymphoma that has not responded following “two or more…
Read More
Multiple Uses for CryoStor in Cell Manufacturing Journal articles recently added to BioLife Solutions’ Evidence Library illustrate several stages during the cell manufacturing process for which CryoStor CS10® cryopreservation solution is applicable. The three articles that follow include several different cell types cryopreserved in CryoStor CS10. An expanded list of cell types biopreserved in BioLife…
Read More
The global impact of COVID-19 on our lives has been profound at virtually every level. Personally, professionally, politically, and economically, the pandemic impacts our lives, our relationships, and how we conduct business. We begin and end the day with the latest news on SARS-CoV-2, and up-to-the-minute COVID-19 data. In between, we must surmount any number…
Read More
The Financial Times identified companies across the Americas that achieved the highest CAGRs in revenue between 2015 – 2018 The FT employed research company, Statista, to survey growth companies across North, Central, and South Americas to list and rank the top 500 participating, independent companies in terms of compound annual growth rate (CAGR) during the…
Read More
Cryopreservation adds flexibility to timelines when working with cells. In the case of cellular therapies, that can mean initial flexibility to schedule patient cell collection, transport cells to the manufacturing facility and initiate manufacturing. Cryopreservation of the final cell therapy product adds flexibility to be able to schedule the return of cells to the patient…
Read More
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, recently announced that based on revenue growth from 2015 to 2018, it has been selected for inclusion on the Deloitte 2019 Technology Fast 500 list. Mike Rice, BioLife President and CEO, commented, “We…
Read More
BioLife Solutions issued a press release August 8, 2019, announcing the execution of a share exchange agreement to purchase the remaining 56% of shares of SAVSU Technologies that BioLife did not previously own. BioLife’s relationship with Savsu spans six years, during the development and growth of the evo® Cold Chain 2.0™ system, encompassing evo® hardware…
Read More
We’re Joining Forces! BioLife Solutions announces intent to purchase SAVSU Technologies shares outstanding. On July 8, 2019, BioLife issued a press release announcing that the company will purchase the remaining 56% of shares of SAVSU that BioLife does not presently own. The acquisition is expected to close within 45 days. BioLife’s relationship with SAVSU spans…
Read More
Posters presenting data for T-cells cryopreserved in CryoStor® cryopreservation solution, authored by BioLife Solutions’ Alireza Abazari, Ph.D., Scientific Applications Director and Aby J. Mathew, Ph.D., Senior Vice President & Chief Technology Officer, were featured during the International Society for Cell & Gene Therapy meeting in Melbourne, Australia, May 29 – June 1, 2019. View the…
Read More